Substance + claimed effects

The Advanced Cardiac Risk Panel is a periodic battery of blood tests and one CT scan that goes well beyond the standard lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides). It bundles ten add-on items that each address a distinct mechanism of cardiovascular and metabolic risk: apolipoprotein B (ApoB) for the count of atherogenic particles; lipoprotein(a) (Lp(a)) for a genetically fixed residual-risk modifier; high-sensitivity C-reactive protein (hs-CRP) for vascular inflammation; fasting insulin and glycated hemoglobin (HbA1c) for insulin resistance and dysglycemia; serum uric acid for metabolic-syndrome and endothelial signal; thyroid-stimulating hormone (TSH) for subclinical thyroid contribution to lipids and arrhythmia; sex hormones (most commonly total and free testosterone, SHBG, oestradiol) for hormonal contributors to vascular and metabolic phenotype; serum 25-hydroxyvitamin D for skeletal-cardiovascular signal; and the coronary artery calcium (CAC) score as a direct, anatomic readout of subclinical atherosclerosis. The claimed effect of the panel is not a treatment effect — none of these tests treat anything — but a refinement of ten-year and lifetime cardiovascular risk estimation, and through that refinement, better-targeted use of high-impact interventions (statins, PCSK9 inhibitors, blood-pressure control, anti-inflammatory or glucose-lowering therapies, lifestyle change). The substance therefore produces consequences mostly on the longevity dimension (via better-targeted prevention of myocardial infarction, stroke, and cardiovascular death), and conditionally on energy, focus, mood, and short-term health when the panel picks up a previously missed thyroid, testosterone, dysglycemia, or vitamin-D issue whose correction is felt within weeks. Costs and effort are non-trivial but bounded.

Evidence by addressing question

mechanism — what each marker measures

ApoB. Every atherogenic lipoprotein particle in plasma — LDL, VLDL, IDL, chylomicron remnants, and Lp(a) — carries exactly one apolipoprotein B-100 molecule on its surface. Counting ApoB therefore counts atherogenic particles directly, while LDL-C measures the cholesterol cargo inside one subset of those particles. The two correlate but diverge meaningfully in roughly 20% of patients (discordance), driven mostly by triglyceride-rich, small-dense particles common in insulin resistance and metabolic syndrome Sniderman et al. 2019. In Mendelian-randomization analyses of UK Biobank, the risk of myocardial infarction tracks the ApoB particle number, not the cholesterol mass: when ApoB is held constant, LDL-C and triglycerides lose their predictive power; the inverse is not true Marston et al. 2022. The European Atherosclerosis Society consensus is that ApoB-bearing lipoproteins are causal, not merely correlative, for atherosclerotic cardiovascular disease Ference et al. 2017.

Lp(a). A genetically determined LDL-like particle with a pro-thrombotic apo(a) appendage. Plasma levels are 80–90% heritable, set by LPA-gene kringle-IV isoform length, and stable from early childhood; lifestyle changes barely move them. Elevated Lp(a) (≥50 mg/dL or ≥125 nmol/L) doubles to quadruples lifetime risk of premature coronary disease and aortic stenosis depending on background risk Kamstrup et al. 2009. A collaborative meta-analysis of 36 prospective studies (n≈126,000) established a continuous, log-linear association between Lp(a) concentration and coronary disease, independent of all other lipid measures Erqou et al. 2009. The 2022 EAS consensus statement now recommends Lp(a) measurement at least once in every adult's lifetime Kronenberg et al. 2022.

hs-CRP. An acute-phase protein synthesized in the liver in response to interleukin-6 signalling, hs-CRP is a non-specific but quantitative readout of systemic inflammation. The Emerging Risk Factors Collaboration pooled 54 cohorts (~160,000 individuals) and found a roughly 1.4× increased coronary risk per standard-deviation increase in log-CRP, attenuated to ~1.2× after adjustment for established factors but still significant Emerging Risk Factors Collaboration 2010. JUPITER (n=17,802) showed that primary-prevention patients with elevated hs-CRP (≥2 mg/L) and normal LDL-C achieved a 44% relative reduction in major vascular events with rosuvastatin 20 mg Ridker et al. 2008. CANTOS (n=10,061) later confirmed the inflammation hypothesis directly: blocking IL-1β with canakinumab reduced cardiovascular events in post-MI patients with hs-CRP ≥2 mg/L, with the benefit concentrated in those whose hs-CRP fell on therapy Ridker et al. 2017.

Fasting insulin and HbA_1c. Fasting insulin (used together with fasting glucose to derive HOMA-IR) rises long before fasting glucose deteriorates — typically by a decade or more — making it the earliest routine clinical signal of insulin resistance. HbA_1c integrates average glycemia across the prior ~90 days. In the ARIC cohort (n=11,092 non-diabetic adults followed 15 years), HbA_1c was a stronger predictor of cardiovascular disease and all-cause mortality than fasting glucose, with risk rising continuously from the 5.0–5.5% range upward Selvin et al. 2010. The American Diabetes Association uses HbA_1c ≥6.5% to diagnose diabetes and 5.7–6.4% for prediabetes ADA 2024; the cardiovascular signal begins well below the prediabetic cutoff.

Uric acid. The terminal product of purine metabolism in humans. Elevated levels cluster with insulin resistance, hypertension, and visceral adiposity (the metabolic-syndrome triad), and large prospective analyses link hyperuricemia to incident hypertension, atrial fibrillation, chronic kidney disease, and cardiovascular events independently of conventional risk factors Borghi et al. 2020. Whether the link is causal or a confounded marker of underlying metabolic disease is unsettled; randomized trials of allopurinol for primary CVD prevention have been small and inconsistent.

TSH. The pituitary-hypothalamic feedback signal that controls thyroid hormone output. Both overt and subclinical hypothyroidism raise LDL-C, ApoB, Lp(a), and diastolic blood pressure; subclinical hyperthyroidism raises atrial-fibrillation and stroke risk. A pooled analysis of 11 prospective cohorts (n=55,287) found that subclinical hypothyroidism with TSH ≥10 mIU/L was associated with a hazard ratio of ~1.9 for coronary heart disease events and ~1.6 for CHD mortality, with risk gradient even from TSH 7–10 mIU/L Rodondi et al. 2010.

Sex hormones. In men, low total or free testosterone is associated with metabolic syndrome, visceral adiposity, and incident cardiovascular events; the question of whether testosterone replacement modifies that risk was the open question that TRAVERSE (n=5,246 hypogonadal men, mean age 63, with or at high risk of CVD) was designed to answer. TRAVERSE found non-inferiority of testosterone gel vs placebo for the primary composite of CV death, non-fatal MI, and non-fatal stroke; secondary signals included higher rates of atrial fibrillation and pulmonary embolism Lincoff et al. 2023. The Endocrine Society limits testosterone therapy to symptomatic men with biochemical hypogonadism documented on at least two morning samples Bhasin et al. 2018. In women, the picture is dominated by perimenopausal oestradiol decline, which accelerates LDL-C/ApoB rise, vasomotor disturbance, and visceral fat accumulation; the CVD-prevention case for menopausal hormone therapy is timing-dependent and beyond this entry's scope.

Vitamin D. 25-hydroxyvitamin D is the circulating storage form, the lab-measured surrogate of vitamin-D status. Observational data are consistent: low 25(OH)D associates with higher all-cause mortality and modestly higher cardiovascular mortality in dose-response fashion (~14% lower mortality per quintile increase in 25(OH)D, plateauing above ~75 nmol/L) Schöttker et al. 2014. The large VITAL trial (n=25,871) found no reduction in major cardiovascular events or invasive cancer with 2,000 IU/day cholecalciferol supplementation over 5.3 years Manson et al. 2019. The honest read: 25(OH)D is a marker of overall health and sun exposure that doesn't fully respond to a pill, but documenting frank deficiency (<30 nmol/L / <12 ng/mL) is still worth doing — that population isn't well represented in the trials.

CAC score. A non-contrast cardiac CT quantifies calcified plaque in the epicardial coronary arteries via the Agatston score. Because calcification is the body's healing response to atherosclerotic injury, the CAC score is a direct count of cumulative lifetime atherosclerotic burden — what the arteries actually look like, not what they're predicted to look like from risk factors. In MESA (n=6,722, multi-ethnic, age 45–84 at baseline), CAC predicted incident coronary events with a hazard ratio of ~7.7 for scores >300 versus zero, after adjustment for conventional risk factors Detrano et al. 2008. At ten-year follow-up the gradient persisted: any CAC raised event rates substantially, with no upper bound to risk at very high scores Budoff et al. 2018. The MESA risk score adds CAC to the Pooled Cohort Equations and reclassifies ~25% of intermediate-risk individuals into higher or lower clinically meaningful categories McClelland et al. 2015.

evidence — does the panel reduce events

The panel does not have a single randomized trial of "test versus don't test" with a hard cardiovascular endpoint — the unit of intervention is a downstream therapy. Evidence therefore comes in two pieces: (1) does each test sharpen the prediction over the standard panel, and (2) does the resulting treatment change reduce events. The prediction case is strongest for ApoB (Mendelian-randomization-grade causal evidence, Marston 2022, Sniderman 2019, Ference 2017), Lp(a) (continuous log-linear association across hundreds of thousands of person-years, Erqou 2009, Kamstrup 2009), and CAC (incremental discrimination, net reclassification index ~0.25 added to Pooled Cohort Equations, Detrano 2008, Budoff 2018, McClelland 2015). The treatment-change case is strongest for ApoB and CAC, both endorsed by the AHA/ACC 2018 cholesterol guideline as risk-enhancers that can move borderline or intermediate-risk patients across the statin-initiation threshold Grundy et al. 2019; the 2019 ACC/AHA primary-prevention guideline gives CAC a Class IIa recommendation in intermediate-risk adults Arnett et al. 2019; ESC's 2021 prevention guideline endorses Lp(a) measurement once in adulthood and ApoB as a preferred alternative to non-HDL-C in metabolic-syndrome phenotypes Visseren et al. 2021, Mach et al. 2020. The hs-CRP case rests on JUPITER and CANTOS — direct evidence that anti-inflammatory therapy reduces events selectively in the inflamed subset Ridker et al. 2008, Ridker et al. 2017. HbA_1c evidence is overwhelming for diabetes management; for cardiovascular risk in non-diabetic adults the ARIC data are convincing Selvin et al. 2010. Uric acid, vitamin D, and TSH each carry observational signals strong enough to monitor but weak enough that the action on an isolated abnormality is usually conservative — repeat, look for symptoms, treat only if other indications meet.

protocol — what to test, when, how often

The defensible default cadence, synthesized across AHA/ACC, ESC, and clinical-practice consensus:

• Lp(a) — once in adulthood. A single measurement is informative for life because levels are genetically fixed. Earlier is better; the value modifies family-history weighting at any age Kronenberg et al. 2022, Nordestgaard et al. 2010.
• ApoB — annually alongside standard lipids; more often (every 3–6 months) when titrating lipid-lowering therapy.
• hs-CRP — annually, with two measurements ≥2 weeks apart when initially elevated (acute illness can spike it transiently); not interpretable within 2–4 weeks of infection, trauma, or surgery.
• Fasting insulin + HbA_1c — annually. HbA_1c needs no fasting; fasting insulin requires a true 10–12 h fast for meaningful HOMA-IR.
• Uric acid — annually; sooner if metabolic-syndrome features or gout history.
• TSH — every 1–3 years in asymptomatic adults; annually after age 50 or with autoimmune-disease history.
• Sex hormones — when symptoms warrant (libido, energy, mood, erectile changes in men; cycle changes, vasomotor symptoms in women). Total testosterone in men should be drawn fasting between 7–10 a.m. and confirmed on a separate day if low Bhasin et al. 2018.
• 25(OH)D — once to establish a baseline; repeat at 3 months after starting supplementation, then annually in temperate-latitude residents and people with limited sun exposure.
• CAC — once between roughly age 40–50 in men and 45–55 in women at intermediate risk, earlier with family history. If score is zero and risk factors remain controlled, repeat at 5–10 years (the "power of zero" is durable but not permanent) Blaha et al. 2017. Any non-zero score generally redirects management rather than triggering serial scans.

The whole-panel cadence is therefore annual for the blood work, with Lp(a) and CAC as essentially one-time-in-life measurements (CAC repeatable at long intervals when zero). Decision points cluster around the CAC result: CAC = 0 with controlled risk factors → conservative management; CAC 1–99 → moderate-intensity statin discussion; CAC 100–299 → high-intensity statin; CAC ≥300 or ≥75th percentile for age/sex → high-intensity statin and consider adjunct therapy Grundy et al. 2019.

contraindications — when not to run the panel

No biological contraindications to the blood work — drawing labs is universally safe. CAC scanning involves a small radiation dose (~1 mSv, comparable to a mammogram or six months of background radiation) and is generally avoided in pregnancy on radiation-precautionary grounds; it is also low yield in patients with established coronary disease (the scan would confirm what is already known and add no decisional value), in the very elderly where almost everyone has some calcium, and in the very young where almost no one does. The more meaningful limits are interpretive: hs-CRP during acute illness, testosterone outside morning hours, vitamin D in summer vs winter, fasting insulin without a true fast.

misconceptions — what most guides get wrong

The dominant misconception is that LDL-C alone is sufficient. It is for many patients — but discordance between LDL-C and ApoB occurs in roughly one in five adults and is particularly common in metabolic-syndrome phenotypes, where small-dense LDL particles carry less cholesterol per particle. In that group, LDL-C systematically under-estimates atherogenic burden and ApoB is the better number Marston et al. 2022, Sniderman et al. 2019. A second misconception: that a zero CAC score "means you're fine." It strongly predicts low 10-year event risk but doesn't render Lp(a), inflammatory burden, or future progression irrelevant Blaha et al. 2017. A third: that vitamin D supplementation will lower cardiovascular risk — VITAL says no, in a generally replete population Manson et al. 2019. A fourth: that "normal-range" Lp(a), TSH, fasting insulin, or HbA_1c are all created equal. Reference ranges are population descriptions, not personal optima — HbA_1c 5.6% is in-range but cardiovascular risk rises continuously below that, and TSH 4.5 mIU/L is in-range but symptomatic and lipid-relevant in many people. A fifth: that testosterone replacement is itself protective — TRAVERSE shows CV non-inferiority, not benefit, with some safety signals to weigh Lincoff et al. 2023.

audience — who the panel is for, by life stage

The panel is calibrated to adults rather than children. Lp(a) is useful as early as adulthood begins, especially with any family history of premature cardiovascular disease (parent event before 55 in men, 65 in women). The blood work as a whole is high value from the late-20s onward whenever any risk factor (family history, central adiposity, hypertension, prediabetes) is present, and roughly default from age 35–40 even in low-risk adults. CAC scanning lands earlier in men than women because subclinical disease becomes detectable earlier in men; default windows are age 40–50 for men and 45–55 for women, shifted earlier with strong family history or elevated Lp(a) or untreated lipids of long standing. Post-CV-event patients are already in secondary prevention and don't need most of this panel for risk stratification — they need it for treatment titration.

alternatives — what else could be done

The closest alternative is the standard lipid panel + Pooled Cohort Equations / SCORE2, the default in most primary-care visits. It captures the dominant axis of risk for most patients and triggers statin discussions at conventional thresholds. The advanced panel adds resolution at the margins where the standard panel under-classifies — discordant ApoB, elevated Lp(a), inflammation, dysglycemia not yet meeting diabetes criteria — and at the centre where CAC reclassifies intermediate-risk patients up or down. Alternative imaging modalities (CT coronary angiography, carotid intima-media thickness) provide more anatomic detail than CAC but at higher cost, radiation, and complexity; in primary prevention they are reserved for cases where CAC is non-informative. Continuous glucose monitoring substitutes for HbA_1c in research contexts but doesn't displace it clinically.

failure-modes — where this goes wrong in practice

The recurring failure is testing without a downstream decision. An elevated Lp(a) with no plan to treat the modifiable factors more aggressively (ApoB, blood pressure, lifestyle) is information for its own sake. An elevated hs-CRP in someone who declines lifestyle change, who has no MI history qualifying them for canakinumab, and whose statin is already maximally tolerated has no actionable next step. A second failure mode is over-reaction to a single value: hs-CRP spikes during viral illness, testosterone varies diurnally and seasonally, vitamin D varies seasonally by 30–50 nmol/L. Single-measurement decisions on labile analytes drive both over-treatment and undertreatment. A third: incidental findings on CAC scanning (pulmonary nodules, thyroid nodules, valve calcification) that trigger downstream investigation and anxiety with negligible probability of clinical benefit. A fourth: laboratory inconsistency. ApoB and Lp(a) assays are standardized but not perfectly portable across labs; mixing assay platforms over time obscures trend.

practicalities — cost, ordering, insurance

The blood work is widely available. In the US, most components except ApoB and Lp(a) are covered by routine primary-care orders; ApoB ranges from $20–60 cash, Lp(a) $25–75. A full advanced panel run direct-to-consumer through services like Quest, Labcorp, or marketplace aggregators typically runs $200–400 annually. CAC scanning runs $75–250 cash in most US markets, rarely covered by insurance for primary prevention. In the UK, NHS access to ApoB and Lp(a) is patchy and CAC scanning typically requires private referral (£100–300). Reporting standards exist (Agatston score, percentile by age/sex/ethnicity from MESA), so a scan obtained at one facility is interpretable elsewhere. Insurance coverage of downstream lipid-lowering therapy (statins, ezetimibe) is universal in most systems; PCSK9 inhibitors and inclisiran require prior authorization tied to documented LDL-C or ApoB elevation on maximally tolerated statin.

history — how the panel came together

The components emerged independently. Lipid panels became routine through the 1980s after the Framingham cohort established cholesterol's role; ApoB was technically measurable from the 1970s but standardized assays only gained traction after the WHO–IFCC reference materials in the 1990s. Lp(a) was identified by Kåre Berg in 1963; its causal role waited for the Erqou collaborative analysis and Kamstrup's Mendelian-randomization work in 2009 to enter guideline conversations. hs-CRP became clinically tractable after Ridker's late-1990s work demonstrating that high-sensitivity assays revealed risk gradients below clinical-inflammation cutoffs, codified by the 2003 AHA/CDC statement and reinforced by JUPITER (2008) and CANTOS (2017). HbA_1c joined the diabetes-diagnostic toolkit formally in 2009 (ADA). CAC scoring was introduced by Agatston in 1990; MESA enrolment from 2000 onward generated the cohort that would establish CAC as the dominant subclinical-atherosclerosis screen. The bundling of all of these into a single "preventive panel" is a recent (2015–2025) phenomenon driven partly by clinical guidelines absorbing the evidence and partly by direct-to-consumer marketing that runs ahead of guidelines.

stakes — what happens if you don't test

The base-rate stakes in the US adult population: roughly half of first MIs occur in people with LDL-C in or near the normal range, in whom standard risk calculators substantially under-classified risk. Lp(a) elevation, present in ~20% of adults, is the most under-diagnosed inherited cardiovascular risk factor and contributes meaningfully to "premature heart disease in someone with normal cholesterol." The trajectory without the panel: standard lipid checks, statin offered or not based on conventional risk, and the first signal of disease being either a stress-test abnormality, an event, or an autopsy finding. The advanced panel doesn't eliminate that trajectory but reshapes its left tail — it identifies a subset of adults whose risk is materially higher than they or their physician believed, in time to act.

payoff — what testing actually delivers

The high-confidence payoff is sharper risk classification with no false sense of safety: CAC = 0 identifies a group with very low 10-year event rates (<1% per year, often called "the power of zero") and lets risk-averse statin candidates back off; CAC ≥100 reclassifies many borderline-risk patients into firm statin candidates whose ten-year benefit is large Blaha et al. 2017, Silverman et al. 2014. Elevated Lp(a) reframes lifetime risk and lowers the threshold for aggressive LDL-C/ApoB lowering. Elevated hs-CRP identifies the residual-inflammatory-risk subset who benefit disproportionately from statins and (in secondary prevention) from anti-inflammatory therapy. Fasting insulin and HbA_1c in the prediabetic range catches metabolic disease a decade before frank diabetes. Thyroid, testosterone, and vitamin D occasionally surface a frankly correctable cause of fatigue, mood disturbance, or lipid abnormality whose treatment is felt within weeks. The compound payoff over a lifetime is years-of-disease-free-life prevented, conditional on doing something with the information.

The credibility range

Optimist case. The components of this panel have stronger predictive validity than any one extension to the standard lipid panel in modern preventive medicine. ApoB carries Mendelian-randomization-grade causal evidence; Lp(a) is the single most under-diagnosed inherited risk factor; CAC out-discriminates Pooled Cohort Equations on its own; hs-CRP identifies the residual-inflammatory-risk subset that JUPITER and CANTOS prove is therapeutically tractable. Run together and acted on, the panel produces a personalized lifetime risk estimate that no calculator-only approach can match, and supports better-targeted use of statins, the single most life-extending pharmacotherapy in primary prevention. The marginal cost is hundreds of dollars per year and one ~$150 scan in a lifetime; the marginal benefit, on the right patient, is years of life. This is the high-leverage end of preventive medicine.

Skeptic case. Most of these markers have not been shown in trials of testing-versus-not-testing to reduce hard cardiovascular endpoints; the case rests on intermediate-outcome reasoning ("ApoB predicts better → therefore measuring ApoB helps"). For the typical low-risk adult under 40 with a normal lipid panel, the panel will find statistical abnormalities that produce anxiety, repeat testing, and occasional incidental-finding cascades with no event reduction. Lp(a)-elevated patients have, until very recently, had no specific therapy — actionability has been limited to "lower ApoB more aggressively," which is what one would have considered anyway. CAC scanning in low-risk adults can cause overdiagnosis-style harms when high scores in stable patients drive invasive workup. hs-CRP is non-specific; vitamin D supplementation doesn't lower CVD; uric acid lowering hasn't been shown to. The direct-to-consumer panel industry has commercial incentives that run ahead of guidelines. For the majority of adults, the standard lipid panel and Pooled Cohort Equations capture most of the decision-relevant signal at a fraction of the cost.

Author's call. The panel is genuinely valuable for adults at intermediate calculated risk, with any family history of premature cardiovascular disease, or with metabolic-syndrome phenotype — the population where standard tools are blurriest and the marginal information most changes management. It is over-prescribed direct-to-consumer to low-risk young adults whose result will be normal or borderline-elevated with no decisional consequence, and under-prescribed in mainstream primary care to the patients who would actually benefit. The components are not equal: ApoB, Lp(a), HbA_1c, and CAC are high-leverage; hs-CRP is useful as a tiebreaker; uric acid, vitamin D, and sex hormones are best ordered when symptoms or phenotype suggest, not as routine screens. The aggregate evidence score is 4 (strong primary-literature support for each component's predictive validity, guideline endorsement for the major ones; not a 5 because randomized "test vs not" trials are absent); controversy is 2–3 (active expert debate about which subset of the panel belongs in routine primary care, about CAC repeat-scan intervals, about the threshold and frequency of Lp(a) measurement, and about direct-to-consumer scope creep).

Stakeholder + incentive map

• Pro-panel. Preventive cardiology societies (AHA, ACC, ESC, EAS, NLA) have steadily expanded the panel's footprint as evidence accumulated; their incentive is preventing avoidable events and improving population risk discrimination. Lipidology specialists and clinical lipid clinics drive earlier adoption of ApoB and Lp(a). Direct-to-consumer testing companies (Function Health, Inside Tracker, Marek Health, Levels-adjacent products) market the panel aggressively; their incentive is subscription revenue and lifetime customer value. Pharmaceutical interests are mixed: statin manufacturers have largely-genericized products with minor remaining incentive; PCSK9/inclisiran/lepodisiran/zerlasiran developers benefit from broader Lp(a) and ApoB testing because their drugs target those specific lipoprotein populations.
• Skeptical / counter-incentive. Primary-care professional societies have historically been more conservative — USPSTF has not endorsed CAC for primary screening at a Grade-B level, citing limited evidence of net benefit at the population level. Health-system payers in single-payer countries (NHS, Canadian provincial systems) limit ApoB, Lp(a), and CAC reimbursement to specific indications. Evidence-based-medicine critics (Vinay Prasad, John Ioannidis, parts of academic primary care) emphasize the absence of testing-versus-not-testing RCTs and the risk of overdiagnosis. Consumer-protection observers flag direct-to-consumer panels' marketing-to-actionability gap.

Population variability

The panel's value is not uniform. The largest absolute risk reductions accrue to patients at intermediate calculated risk (5–20% ten-year risk), where the panel reclassifies meaningfully in either direction. In low-risk young adults (under 40, no family history, lean, lipid-normal), the panel mostly confirms low risk; Lp(a) is the exception — its lifetime importance is set in adolescence and the test is informative whenever it is done. In high-risk and established-disease patients, the panel adds little to the secondary-prevention treatment plan (already on high-intensity statin, ezetimibe, often PCSK9 inhibitors). Ancestry affects Lp(a) (Black populations average ~2-fold higher levels than white populations, with similar per-mg/dL risk gradient) and CAC (South Asian and East Asian populations have lower mean CAC at given risk levels but higher event rates per unit calcium — the score's calibration is best in Northern European populations). Hormone reference ranges are age- and assay-specific and require careful interpretation in women through the menopausal transition and in older men. CAC scanning is most informative in the 40–70 age band; below that, calcium hasn't had time to deposit and below-detection-threshold disease is common; above that, ubiquitous calcium loses individual discriminative power.

Knowledge gaps

• Lp(a) lowering. Pelacarsen (HORIZON, completing 2025–2026), olpasiran (OCEAN(a)-Outcomes), lepodisiran, and muvalaplin are in late-phase trials; whether substantial Lp(a) lowering reduces hard CVD endpoints is the field-defining open question. Positive results would dramatically reshape Lp(a) testing's actionability.
• CAC repeat intervals. The optimal interval between scans for patients with CAC = 0 is uncertain; current 5–10-year defaults are guideline expert consensus, not trial-derived.
• Anti-inflammatory primary prevention. CANTOS confirmed the inflammatory pathway in secondary prevention; primary-prevention trials of low-dose colchicine or IL-6 inhibitors in hs-CRP-elevated patients are not yet definitive.
• Insulin-resistance treatment in pre-prediabetes. Whether early metformin, GLP-1 agonism, or lifestyle intervention triggered by elevated fasting insulin (HOMA-IR) but normal HbA_1c changes cardiovascular trajectory is an active research area; the trial endpoints will take a decade.
• Population-scale CAC screening. Whether expanding CAC scanning to the broader intermediate-risk population yields net benefit, factoring in cost, radiation, incidental findings, and downstream care, has not been settled by a randomized trial — observational data are positive but the head-to-head against optimized risk-calculator use is unproven.
• Direct-to-consumer testing harms. The rate of clinically meaningful incidental findings, false-positive cascades, and anxiety-driven over-treatment from broad-panel direct-to-consumer testing has not been quantified at scale.

Scope vs brief. The brief named ten components (ApoB, Lp(a), hs-CRP, fasting insulin, HbA_1c, uric acid, TSH, sex hormones, vitamin D, CAC). All ten are covered end-to-end in the mechanism section; protocol, evidence, and misconceptions touch each one again. No silent narrowing.

Category choice. Filed under screening (Screening & Prevention) rather than medical. The panel is a periodic test bundle, not a treatment.

Cadence choice. Set to yearly as the dominant cadence — most of the blood work runs annually. Lp(a) and CAC sit outside that rhythm (once-in-life and infrequent respectively); the protocol section names both explicitly so the cadence field's compression is not misleading.

Action choice. test is the obvious fit — the substance is "gather your own data." Not do because the panel itself treats nothing; downstream actions ride on the results.

Rating tensions.

• longevity 4 vs 5: the panel earns 4 by reshaping who gets statin therapy at what intensity and when — the underlying lifesaving move sits one layer downstream. A pure-test entry rarely earns 5; that score is reserved for the interventions themselves.
• energy, focus, mood, health_short_term at 1 each: the call was whether to score these at 0 or 1. Scored 1 because the TSH, testosterone, and vitamin-D components legitimately surface correctable conditions whose treatment is felt within weeks in a minority of patients. Both pitches and justifications flag the conditionality so the rank card is not misleading.
• evidence 4 vs 5: deliberately not 5 because no randomized "test vs no test" trial with hard CV endpoints exists for the panel as a unit; the case is component-by-component intermediate-outcome and treatment-response evidence. The bar in meta.md §6 is "name 2+ rigorous trials" for 5, which would not honestly hold at the panel level even though it would at the ApoB-and-CAC sub-level.
• controversy 3: USPSTF is more conservative than ACC/AHA on CAC; primary-care literature more conservative than preventive-cardiology literature on routine Lp(a) and ApoB. Active expert debate without foundational camps.

Audience left open. Considered scoping to 40+ because CAC and most components are higher value in midlife. Left unscoped because Lp(a) is essentially once-in-life and informative whenever it is done — early adulthood is the right window for that one component. The article body handles the by-age guidance in the protocol section so the scoping carries.

Contraindications left empty. The closed vocabulary tokens do not fit. Pregnancy avoids CAC scanning on radiation grounds, but the blood work is universally safe — adding pregnancy would over-scope the whole panel. Better handled in prose (mechanism / practicalities) than as a top-level contraindication.

Separate-entry candidates.

• Coronary Artery Calcium Score on its own — likely warrants a dedicated entry once the catalogue's screening section densifies. The mechanism and decision-driving rationale in this entry could be lifted and deepened (zero-score durability, repeat intervals, Agatston vs volume scoring).
• ApoB as the Cardiovascular Risk Number — already on the catalogue's good-title-examples list in the headline spec; deserves its own entry with the discordance-with-LDL-C story told end-to-end.
• Lp(a) once in a lifetime — narrowly scoped entry on the single inherited risk factor and its emerging therapeutics (pelacarsen, olpasiran).
• Subclinical Hypothyroidism — TSH-driven cardiovascular signal and the lipid-thyroid link deserve their own treatment.

Future-link candidates. When they exist: standard lipid panel, blood pressure measurement protocol, statin therapy, sleep apnea screening, the conversation-with-a-preventive-cardiologist entry. Out-of-scope section signposts these in reader-friendly form.

Deliberate omissions. Did not cover homocysteine (declining evidence, dropped from most contemporary panels), oxidized LDL (not assay-standardized for clinical use), or NMR particle-subclass profiling (more granular than ApoB but without proportional decision-value at primary-care level). Left CT coronary angiography out of the protocol body — it is a downstream test on positive CAC, not a screening tool.